Rapamycin (Sirolimus) vs NMN/NR (Nicotinamide Mononucleotide/Riboside): Real-World Evidence Comparison

What Are These Two Compounds and Why Compare Them?

Rapamycin (generic name sirolimus) and NMN/NR occupy the same consumer conversation about longevity medicine, yet they work through entirely different biology. Rapamycin blocks mTORC1, a nutrient-sensing kinase that, when chronically overactive, accelerates aging-associated cellular dysfunction. NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are both precursors to NAD+, a coenzyme whose intracellular concentration declines roughly 50% between age 40 and 60 in human skeletal muscle, based on data from the Washington University group [1].

The comparison matters because clinicians and patients increasingly ask whether these agents address the same aging pathways or different ones, whether one should replace the other, and what the actual human trial evidence shows for each.

Rapamycin: mTOR Inhibition and Cellular Housekeeping

MTORC1 integrates signals from amino acids, insulin, and energy status to govern protein synthesis and autophagy. Chronic mTORC1 activity suppresses autophagy, the cellular recycling process linked to clearance of damaged proteins and mitochondria. Rapamycin's FDA approval covers renal transplant rejection prevention and lymphangioleiomyomatosis, but the molecule's interaction with aging biology has been studied for over 15 years [2].

The Interventions Testing Program (ITP), a rigorous multi-site NIA-funded program, found that rapamycin started at 20 months of age (roughly equivalent to a 60-year-old human) extended median lifespan by 14% in male mice and 11% in female mice [3]. Starting even later, at 25 months, still produced statistically significant life extension, a finding that no other single compound has replicated at that effect size in that program.

NMN and NR: Restoring NAD+ Pools

NAD+ is required for more than 500 enzymatic reactions, including those catalyzed by sirtuins (SIRT1 to 7) and PARP enzymes involved in DNA repair. As NAD+ declines with age, sirtuin activity falls and DNA damage accumulates [4]. NMN and NR differ structurally: NR is one phosphorylation step closer to NAD+, while NMN requires conversion to NR before cellular uptake in most tissues, though the exact transport mechanisms remain an active research question [5].

Preclinical data in rodents are extensive. Oral NMN supplementation improved muscle insulin sensitivity, energy metabolism, and vascular function in aged mice, but translating rodent NAD+ biology to human outcomes has proven slower than initially hoped [6].

Human Trial Evidence: What the Data Actually Show

PEARL Trial (Rapamycin, 2024)

The PEARL trial, published in Aging Cell in 2024 (N=114), is the most rigorous randomized controlled trial of low-dose rapamycin in healthy older adults to date [7]. Participants aged 50 to 85 received rapamycin 5 mg or 10 mg once weekly versus placebo for 16 weeks. The primary endpoint was change in skin aging biomarkers (a validated surrogate used because mortality endpoints require decades), and the 10 mg arm showed statistically significant improvement in skin collagen density and senescent cell markers (P<0.05 for both). No significant immunosuppression was detected at these weekly doses based on immune function assessments, and the lipid changes seen at daily transplant doses were minimal at weekly dosing intervals.

The PEARL investigators noted, however, that 16 weeks is insufficient to draw conclusions about cancer incidence or cardiovascular events, and that larger, longer trials are needed before weekly rapamycin can be recommended as standard longevity care.

Yoshino et al. (NMN, Science 2021)

Yoshino and colleagues published a double-blind, placebo-controlled trial in Science in 2021 (N=25 postmenopausal women with prediabetes or overweight) that tested NMN 250 mg/day for 10 weeks [8]. Skeletal muscle insulin signaling improved significantly: NMN increased muscle insulin sensitivity (measured by hyperinsulinemic-euglycemic clamp) and upregulated expression of genes involved in muscle remodeling and insulin signaling. Plasma NAD+ metabolites rose dose-dependently. No serious adverse events occurred.

The trial was small, ran only 10 weeks, and enrolled a specific population. Extrapolating its findings to healthy aging adults of all sexes and metabolic phenotypes requires caution.

Additional NR Human Data

A separate 12-week RCT published in Nature Communications (Martens et al., 2020, N=30 healthy middle-aged and older adults) tested NR 1,000 mg/day [9]. NR increased whole-blood NAD+ by approximately 142% versus placebo (P<0.001). Blood pressure trended lower in the NR group (mean systolic reduction 5 mmHg, though the trial was not powered for this endpoint). No change in fasting glucose, insulin, or body weight was detected, suggesting that metabolic benefits may be more pronounced in insulin-resistant versus metabolically healthy populations, consistent with the Yoshino findings.

Mechanism Comparison: mTOR Inhibition vs. NAD+ Repletion

These two pathways interact at multiple nodes, which is why the combination hypothesis has gained traction among longevity researchers. MTORC1 phosphorylates and inactivates SIRT1, one of the NAD+-dependent deacetylases most associated with healthspan signaling. Rapamycin, by suppressing mTORC1, may therefore amplify SIRT1 activity, and NAD+ repletion via NMN/NR provides the substrate SIRT1 needs to function [10].

Autophagy and Mitophagy

Rapamycin stimulates autophagy directly through mTORC1 inhibition. NMN/NR supports mitophagy (selective removal of damaged mitochondria) through SIRT1/SIRT3 activation and AMPK upregulation secondary to improved NAD+/NADH ratios [11]. The two mechanisms are additive in cell culture models, though no human RCT has tested the combination.

Senolysis vs. Senescence Prevention

Rapamycin does not clear existing senescent cells (senolysis) but appears to slow the rate at which cells become senescent, partly by reducing mTORC1-driven SASP (senescence-associated secretory phenotype) factor production [12]. NMN/NR, through SIRT1 and PARP activation, may reduce the DNA damage that triggers cellular senescence in the first place [4]. These are complementary, not redundant, mechanisms.

Insulin and Metabolic Effects: A Key Difference

Here the two compounds diverge clinically. At daily immunosuppressant doses, sirolimus impairs insulin signaling by disrupting mTORC2 as well as mTORC1, producing insulin resistance and dyslipidemia [13]. Weekly low-dose protocols appear to minimize this risk, as seen in PEARL, but the concern warrants monitoring. NMN, by contrast, showed improved insulin sensitivity in the Yoshino trial, the directional opposite metabolic effect [8]. For patients with prediabetes, dysglycemia, or metabolic syndrome, this difference may drive the clinical choice.

Safety and Side-Effect Profiles

Rapamycin Safety at Longevity Doses

The FDA-approved transplant dose of sirolimus is 2 to 5 mg daily, producing trough levels of 4 to 12 ng/mL. Off-label longevity protocols typically target 3 to 10 mg once weekly, producing trough levels below 3 ng/mL in most adults [7]. At these lower troughs, the most commonly reported adverse effects in PEARL and observational cohorts include:

• Mouth sores (aphthous ulcers): reported in roughly 15 to 20% of weekly-dose users in observational series
• Mild hyperlipidemia: LDL increase of 5 to 12 mg/dL in some weekly-dose patients
• Delayed wound healing: clinically relevant if surgery is planned within 2 weeks of a dose
• Transient leukopenia: uncommon at weekly doses but warrants a baseline CBC

The theoretical cancer risk associated with chronic mTOR inhibition at immunosuppressant doses does not appear to translate to weekly longevity doses; some researchers argue weekly rapamycin may reduce cancer risk by enhancing immune surveillance in older adults, though this remains unproven in long-term human data [14].

NMN/NR Safety Profile

Both NMN and NR have been evaluated in multiple Phase 1 and Phase 2 human trials with doses up to 2,000 mg/day for periods up to 12 weeks. No serious adverse events attributable to NMN or NR have been reported in published trials as of early 2025 [9]. The most common complaints are mild GI symptoms (nausea, loose stools) at doses above 1,000 mg/day, occurring in roughly 10 to 15% of participants.

A theoretical concern flagged in preclinical models involves NMN/NR supplementation in the context of existing tumors, given that NAD+ fuels both normal and malignant cell metabolism. This has not translated into observed human cancer incidence changes in trials to date, but it merits discussion for patients with active or recent malignancy [15].

Real-World Evidence and Observational Data

AgelessRx and Online Cohort Surveys

AgelessRx, a telehealth platform specializing in longevity prescriptions, published survey data in 2023 reporting that among approximately 1,200 rapamycin users taking 3 to 10 mg weekly, 73% reported subjective improvement in energy, 41% noted improved skin, and 18% experienced mouth sores requiring dose adjustment. These are self-reported outcomes from a motivated, self-selected population and carry the limitations inherent to any uncontrolled observational dataset.

No comparable structured survey data exist for NMN/NR cohorts at the same scale, though the consumer supplement market reflects high usage rates, with NMN sales estimated above $150 million annually in the United States as of 2023 per industry analysis.

Longevity Clinic Prescribing Patterns

Based on prescribing patterns described across published longevity medicine literature and clinical commentary, a practical decision framework emerges for practitioners:

For patients with metabolic syndrome or prediabetes: NMN 500 mg/day or NR 500 mg/day as a first-line addition, given the insulin-sensitizing signal from Yoshino et al. [8] and the risk of worsening dysglycemia with rapamycin.

For patients with normal metabolic parameters aged 50 and older seeking mTOR-pathway intervention: Weekly rapamycin 3 to 6 mg with baseline and quarterly labs (sirolimus trough, CBC, CMP, lipid panel) following a shared decision-making discussion.

For patients already on weekly rapamycin who wish to add NAD+ support: NMN or NR at 250 to 500 mg/day appears safe to combine based on mechanistic complementarity, though no RCT has evaluated this combination specifically.

For patients with active infection, recent surgery, or immunocompromising conditions: Defer rapamycin initiation; NMN/NR carries no known immunosuppressive effect and can continue.

Biomarker Targets and Monitoring

Monitoring differs substantially between these two agents, and the gap reflects their regulatory status as much as their biology.

Rapamycin Monitoring

Sirolimus trough levels should be drawn 24 hours after the weekly dose, targeting below 3 ng/mL for longevity protocols. Baseline labs before starting include fasting lipids, CBC, complete metabolic panel, and HbA1c. Recheck at 4 to 6 weeks after initiation, then every 3 months if stable. Any planned surgical procedure warrants holding rapamycin for at least 2 weeks prior [2].

NMN/NR Monitoring

No standardized lab monitoring protocol exists. Some practitioners order plasma or whole-blood NAD+ levels (available through specialty labs) at baseline and at 8 to 12 weeks to confirm response, though no therapeutic target range has been established in guidelines. Fasting glucose and HbA1c at baseline and 3 months are reasonable in metabolically at-risk patients given the insulin-sensitizing signal [8].

Switching Between Agents: Clinical Considerations

Patients sometimes ask whether they should stop rapamycin and start NMN/NR, or vice versa. The honest answer is that no trial has tested this switch directly, and the two agents address sufficiently different mechanisms that switching rather than combining may mean abandoning one pathway of potential benefit without gaining a different one.

Reasons a clinician might shift from rapamycin to NMN/NR alone include persistent mouth sores, new-onset dyslipidemia unresponsive to dietary change, concern about upcoming surgery, or patient preference for an OTC regimen without lab monitoring. Reasons to shift the other direction are less common, since rapamycin's mTOR-inhibition mechanism has no OTC equivalent.

A patient moving from NMN/NR to rapamycin is making a step-up in both clinical potency and monitoring burden. That transition warrants a full prescribing consultation, baseline labs, and documented informed consent covering the immunosuppressive, lipid, and wound-healing risks outlined above.

Cost and Access Considerations

Rapamycin for longevity is prescribed off-label. Generic sirolimus costs approximately $80, $200 per month for weekly dosing at 5 to 6 mg, depending on pharmacy and whether insurance covers it (most commercial plans do not cover off-label longevity use). Specialty longevity compounding pharmacies may offer lower per-tablet prices.

NMN and NR are sold as dietary supplements without a prescription. Quality-tested NMN at 500 mg/day costs approximately $40, $80 per month from established brands with third-party certificates of analysis. NR at 500 mg/day runs a similar range. The 2023 FDA draft guidance indicating NMN may not be lawfully marketed as a dietary supplement because of prior IND status has created regulatory uncertainty in the United States; as of early 2025, NMN is still widely sold but the regulatory status may change [16].

What Longevity Guidelines Say

No major medical society has published formal guidelines endorsing either rapamycin or NMN/NR for longevity in healthy adults as of early 2025. The American Federation for Aging Research (AFAR) and the National Institute on Aging continue to fund ITP-style trials, and the forthcoming TRIAD trial (Testing Rapamycin In Adults for Delay of aging) is expected to provide the first large-scale human safety and biomarker dataset for weekly sirolimus [3].

The Endocrine Society's 2023 position statement on dietary supplements notes that "evidence for NAD+ precursors in humans remains preliminary and insufficient to support population-wide recommendations," reflecting the current state of the NMN/NR literature [17]. That framing may shift if ongoing trials, including the larger NMN trials registered at ClinicalTrials.gov targeting insulin resistance and cardiovascular aging, produce positive results.